PSL has developed a dispensary isolator with a contained drum hoist mechanism for highly potent API production.
Powder Systems Ltd (PSL), a manufacturer of filtration, drying, and contained powder handling products, has developed a dispensary isolator with a contained drum hoist mechanism. The company is exhibiting this nano-containment technology at ACHEMA.
According to PSL, the dispensary isolator will be installed into a GMP manufacturing plant in the United States this year. Numerous operations will be processed inside this nano-containment isolator, including drum offloading with safe drum chamber, dispensing, weighing, and sampling. All these operations will be carried out with a containment performance of 30–100ng/m³ in 8 hours time-weighted average (TWA) that will be tested and certified by a third party hygienist prior to starting the production.
PSL dispensary isolator
Also on display is PSL’s innovative Lab Nutsche Filter Dryer, the GFD, which is a smaller version of a production agitated nutsche filter dryer. The GFD allows easy lab-scale filtration and drying with the same reliability and benefits as full-size filter dryers. It suits laboratories need and comes in three filtration area sizes. This vacuum lab filtration and drying unit is now available in stainless steel for higher-pressure requirement. Because of its direct scale-up abilities, it is suitable for feasibility studies and trials before a company invests in a large scale nutsche agitated filter dryer.
Source: PSL, Hall 5.1, Stand C31
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.